

January 30, 2025

To,
The Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001
Scrip Code: 540737

Dear Sir / Ma'am,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Press Release.

In terms of provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that the Company has signed MOU for Long-Term Strategic Supply with one of the foremost players in the Japanese market today i.e. on January 30, 2025.

A copy of the Press Release in this regard which is self-explanatory is attached herewith.

Kindly take the same on your record.

Thanking you,
Yours Faithfully,
For Shree Ganesh Remedies Limited

Aditya Patel
Company Secretary

SHREE GANESH REMEDIES LIMITED ANNOUNCES MOU WITH LEADING JAPANESE COMPANY

In a significant development, Shree Ganesh Remedies Limited (SGRL) is pleased to announce the execution of a Long-Term Strategic Supply Agreement (SSA) with one of the foremost players in the Japanese market. The agreement, formalised on 30th January 2025, is set for an initial term of three years, with the potential for extension by an additional two years.

Under this strategic partnership, SGRL will engage in contract manufacturing for a total of three innovative products, which are poised to make their debut as the first of their kind in India. These products will be developed employing advanced methodologies in Chlorination and Reduction chemistry.

The Memorandum of Understanding (MOU) serves as a pivotal starting point for SGRL's strategic contract manufacturing venture, aimed at addressing the demand within the Specialty Chemicals markets.

Commenting on this landmark agreement Gunjan Kothia, Whole Time Director of Shree Ganesh Remedies Limited, stated,

"We are thrilled to embark on this strategic alliance with a leading Japanese company. This partnership not only underscores our capabilities in specialty chemicals but also positions us to cater effectively to the growing demands of international markets. We are committed to leveraging our expertise to deliver exceptional value and innovation through this collaboration."

ABOUT SHREE GANESH REMEDIES LIMITED (SGRL)

Shree Ganesh Remedies Limited is a leading player in the chemical manufacturing industry, specialising in pharmaceutical intermediates and specialty chemicals. With over 19 years of excellence, the company is renowned for its unparalleled expertise in advanced chemical synthesis and complex chemical reactions. Strategically expanding its operations, Shree Ganesh Remedies is focused on innovation through strategic R&D investments and state-of-the-art infrastructure. The company serves over 20 countries, including key markets in the EU and the US, offering tailored solutions to global industry leaders. Committed to sustainable practices, Shree Ganesh Remedies holds multiple accreditations, including ISO certifications and EcoVadis Bronze. With ongoing expansions at its Ankleshwar and Dahej sites and a strategic shift towards complex niche specialty chemicals, the company is well-positioned for future growth and continues to deliver high-quality, custom manufacturing solutions to its clients.

CONTACT US:

Aditya Patel
Company Secretary
Shree Ganesh Remedies Limited
Email: investors@ganeshremedies.com

Abhishek Mehra
Investor Relations Advisors
TIL Advisors Private Limited
Email: abhishek@theinvestmentlab.in
Mobile No.: +91 95588 14500

Certain statements in this document that are not historical facts are forward looking statements. Such forward looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. Shree Ganesh Remedies Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.